Pancreatic Transdisciplinary Cancer Team

group of people standing together in a hallway with some holding purple star balloons

The goal of the Pancreatic Transdisciplinary Cancer Team is to bring expertise from different disciplines in basic and clinical research to advance our understanding of pancreatic cancer and to translate that information to clinical trials to improve patient care in South Carolina.

The team consists of members with expertise in basic biology, oncology, pathology, surgery, population science, pharmacology, engineering, and informatics and biostatistics.

Co-Leaders

2022 Presentation Schedule

January 18

“Investigating the role of ceramides in muscle wasting in pancreatic cancer-induced cachexia”

Victoria Spadafora
Ph.D. Student (Guttridge Lab)
MUSC

February 15

“Novel insights into therapeutic targeting of KRAS: conventional wisdom is not always right!”

John P. O'Bryan, Ph.D.
Professor, Department of Molecular Pharmacology and Experimental Therapeutics
MUSC

March 15

Joint meeting with Colon TCT: “Novartis GI pipeline presentation”

 

April 19

“New biotherapeutics for the treatment of pancreatic ductal adenocarcinoma”

Nate Dolloff, Ph.D.
Associate Professor, Department of Molecular Pharmacology and Experimental Therapeutics
MUSC

May 17

“The Stat3/Pten Axis in the PDAC macroenvironment”

Mike Ostrowski, Ph.D.
Professor, Department of Biochemistry and Molecular Biology
MUSC

June 21

“Locoregional treatments for inoperable pancreatic cancer”

Thor Johnson, M.D.
Department of Radiology and Radiological Science
MUSC

July 19

“KRASG12R allele-specific metabolic reprogramming alters therapeutic sensitivity”

Aaron Hobbs, Ph.D.
Assistant Professor, Department of Molecular Pharmacology and Experimental Therapeutics
MUSC

August 16

“New resources: organoids and orthotopic models for PDAC”

Aaron Hobbs, Ph.D.
Assistant Professor, Department of Molecular Pharmacology and Experimental Therapeutics
MUSC

David Wang, M.D., Ph.D.
Research Assistant Professor, Department of Pediatrics
MUSC

September 20

“Origin and heterogeneity of pancreatic cancer associated fibroblasts”

Han Lu, Ph.D.
Postdoctoral Fellow (Ostrowski Lab)
MUSC

October 18

“Progress toward the total synthesis of Aleutianamine: a highly potent and selective inhibitor of pancreatic cancer cells in vitro”

Scott Wyer
Ph.D. Student (Hamann Lab)
MUSC

November 15

“Defining the KRAS mutant specific interactome in pancreatic cancer”

Rachel Burge
Ph.D. Student (Hobbs Lab)
MUSC

December 13

“Update on GI clinical trials: current studies and future directions”

William Lancaster, M.D.
Department of Surgery
MUSC

Team Members

Tim Barnoud, Ph.D.
Ashton Basar
Rachel Burge
Xiaoyan Chen, Ph.D.
Ben Christopher
Toros Dincman, M.D., Ph.D.
Nathan Dolloff, Ph.D.
Badih Joseph Elmunzer, M.D.
Marvella Ford, Ph.D.
Erin Forster, M.D.
Mark Hamann, Ph.D.
Lu Han, Ph.D.
George Hanna
Nour Hijazi
Aaron Hobbs, Ph.D.
Brenda Hoffman, M.D.
Joseph Karam
Nancy Klauber-DeMore, M.D.
Stacey Kneeshaw
David Lewin, M.D.
Katie Marelia, Ph.D.
David Marshall, M.D.
Dian Mayasari, Ph.D.
Spencer Miller, Ph.D.
Robert Moran, M.D.
Katherine Morgan, M.D.

John O’Bryan, Ph.D.
Besim Ogretmen, Ph.D.
Elizabeth O’Quinn
Michael Ostrowski, Ph.D.
Sophie Paczesny, M.D., Ph.D.
Benjamin Pryce, Ph.D.
Colleen Quaas, Ph.D.
Vinodh Rajagopalan, Ph.D.
Krishna Ramajayam, Ph.D.
Daniel Reuben, M.D.
Lety Reyes
Martin Romeo, Ph.D.
Matt Rhett, Ph.D.
Reeder Robinson, Ph.D.
Ulyss (Karl) Roesner
Samaneh Saberikashani, Ph.D.
Devadoss Samuvel, Ph.D.
Sudarshana Sharma, Ph.D.
Victoria Spadafora
Jane Talbot
David Wang, M.D., Ph.D.
Hongjun Wang, Ph.D.
Michael Whaby
Michael Yost, Ph.D.
Mariyam Zuberi, Ph.D.